Business
Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs
Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs.
About this update from Electromedical Technologies, Inc.
[{"type":"text","content":"\n\n\n\nElectromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nElectromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs\nPR Newswire\nSCOTTSDALE, Ariz., June 3, 2021\n\n\n\n- Studies could lead to development of next-generation targeted devices to effectively treat chronic pain\n- Stage I research programs designed to study how electro-modulation communicates to cells\n- Program objective to decipher impacts of alternating electrical fields on cell signaling and generating cellular response\n- Leveraging the executed agreement EMED and Nazarbayev plan to begin the IDE process with the FDA\n SCOTTSDALE, Ariz., June 3, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the \"Company\"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+®, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs. These Stage I programs will study how electro-modulation communicates to cells by modifying intracellular signaling events and altering physiological cellular response.\nElectro-modulation therapies (electroceuticals) are conducted and widely applied in medicine today utilizing a variety of frequencies to reduce chronic pain. A front page TIME magazine article noted: \"Electroceuticals \"are the next wave of new treatments we will have to treat disease,\" says Kris Famm, president of Galvani Bioelectronics, a biotech collaboration between Glaxo-Smith-Kline and Google's Verily that is focused on developing electricity-based therapies (https://time.com/5709245/bioelectronic-medicine-treatments/). Going forward, researchers hope to learn how alternating electrical fields affect cell physiology and induce their effects. \nThe main challenge is to define specific electrical frequencies that alter cell physiology ...